Clinical Trial Update: Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L [Phase 3]

View source ↗

Summary

Phase 3 placebo-controlled clinical trial update for Hepcortespenlisimut-L in hepatocellular carcinoma (liver cancer).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Liver Cancer

Drugs mentioned

• Hepcortespenlisimut-L (hepcortespenlisimut-L)

Snippet

Sponsor: Immunitor LLC | Conditions: Hepatocellular Carcinoma, HCC | Phase 3 | Status: UNKNOWN